Sugi Predict

Sugi Predict / Compounds / SCHEMBL191353

SCHEMBL191353

SCHEMBL191353

CC(=O)N1CCC(C(=O)O)CC1

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.55
▸ CYP1A2 P05177 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ EPHX2 P34913 2/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ RAB9A P51151 1/20 0.44
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8947886 1.00 LMNA (0.55) LMNACYP1A2TDP1GAAL3MBTL1
Hydrochloric Acid SCHEMBL1835887 0.98 LMNA (0.53) LMNACYP1A2TDP1GAAL3MBTL1
SCHEMBL14239713 0.88 CHRM1 (0.46) LMNAGAAL3MBTL1MAPTALDH1A1
Trifluoroacetic Acid SCHEMBL5234086 0.88 LMNA (0.50) LMNAGAAL3MBTL1MAPTEPHX2
SCHEMBL14752931 0.86 LMNA (0.47) LMNAGAAL3MBTL1MAPTEPHX2
SCHEMBL3282152 0.86 LMNA (0.47) LMNAGAAL3MBTL1MAPTEPHX2
SCHEMBL12233204 0.86 LMNA (0.47) LMNAGAAL3MBTL1MAPTEPHX2
SCHEMBL190928 0.83 CYP1A2 (0.48) CYP1A2TDP1EPHX2EPHX1
SCHEMBL22904686 0.83 EPHX2 (0.44) LMNACYP1A2TDP1EPHX2EPHX1
SCHEMBL8279747 0.82 LMNA (0.52) LMNAGAAL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110167944-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-08-23 — — CN claimed
CN-111108109-A Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors 利奥制药有限公司 2020-05-05 — — CN claimed
CN-110437136-A 1- virtue oxygen ethyl piperidine -4- base methanone derivatives and its preparation method and application UNIV SOUTHEAST 2019-11-12 — — CN claimed
CN-110099905-A SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-06 — — CN claimed
EP-2872504-B1 ARYL SULTAM DERIVATIVES AS RORc MODULATORS HOFFMANN LA ROCHE (CH) 2016-11-16 — — EP claimed
US-9453023-B2 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US claimed
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 — — US claimed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 — — US claimed
EP-2882725-A1 SUBSTITUTED HETERO-AZEPINONES F. Hoffmann-La Roche AG (CH) 2015-06-17 — — EP claimed
EP-2872504-A1 ARYL SULTAM DERIVATIVES AS RORc MODULATORS F. Hoffmann-La Roche AG (CH) 2015-05-20 — — EP claimed
EP-1299356-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-02-11 — — EP claimed
US-20030176695-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ALANINE ALEXANDER (FR) 2003-09-18 — — US claimed
US-20030153555-A1 Novel compounds ASTRAZENECA AB (SE) 2003-08-14 — — US claimed
US-20030139404-A1 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2003-07-24 — — US claimed
US-20030125318-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ALANINE ALEXANDER (FR) 2003-07-03 — — US claimed
EP-1303272-A2 BENZOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 — — EP claimed
EP-1299356-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2003-04-09 — — EP claimed
US-20020045615-A1 Benzothiazole derivatives with activity as adenosine receptor ligands F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 — — US claimed
WO-2001097786-A2 BENZOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-12-27 — — WO claimed
WO-2001098272-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-12-27 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES CCNY, CCNE1, CCND3 LMNA 2738/4885CYP1A2 544/4885TDP1 2186/4885
US-20030125318-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 LMNA 3923/4885CYP1A2 1431/4885TDP1 1246/4885
US-20030176695-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 LMNA 3923/4885CYP1A2 1431/4885TDP1 1246/4885
US-20030153555-A1 Novel compounds RPS4Y1, RPS4X, UGT2B7 LMNA 2215/4885CYP1A2 203/4885TDP1 4549/4885
US-20020045615-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 LMNA 3923/4885CYP1A2 1431/4885TDP1 1246/4885
US-20030139404-A1 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents NAT1, CYP1A1, UGT1A1 LMNA 1312/4885CYP1A2 14/4885TDP1 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.